Lulizumab
Based on 1 publication(s) in Google Scholar
Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is an anti-CD28 domain antibody antagonist. Lulizumab inhibits T-cell activation by selectively targeting the CD28 signal. In a sensitized non-human primate kidney transplantation model, when combined with Carfilzomib (HY-10455), Lulizumab can regulate immune cells and prolong the survival time of the graft.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: ≥95.0%
- CAS No.: 2235419-62-0
- Masse moléculaire:12.01 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Lulizumab
More
Activité biologique
V-kappa
Human
CD28
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Macaca mulatta were sensitized by performing swapping skin transplants of 3cm diameter patches of dorsal skin between individuals of each pair twice, 8 weeks apart. Then they underwent kidney transplantation[2].
-
Dosage:12.5 mg/kg
-
Administration:Subcutaneous injection; once a week for 4 weeks
-
Result:Led to a significant reduction in donor-specific antibody levels.
Decreased the number of follicular helper T cells and proliferating B cells in the lymph nodes.
Increased the proportion of naïve CD4 T cells and naïve B cells in circulation, maintained the frequency of regulatory T cells.
Significantly prolonged the median survival time of the grafts.
Caused animals to ultimately experience antibody-mediated rejection and graft failure.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
V-kappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 106 Jurkat cells with Lulizumab (HY-P99302, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor® 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 2235419-62-0
-
Appearance Liquid
-
Masse moléculaire 12.01 kDa
-
Color Colorless to light yellow
-
SMILES
[Lulizumab]
-
Synonyms
BMS-931699 Antibody
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Pureté et documentation
-
Fiche technique (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Fernandes JC. Therapeutic application of antibody fragments in autoimmune diseases: current state and prospects. Drug Discov Today. 2018 Dec;23(12):1996-2002. [Content Brief]
[2]. Schroder PM, et al. Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model. Kidney Int. 2021 Jan;99(1):161-172. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz